CTRI/2013/12/004183已完成未知
tility of an additional HIV test near term during pregnancy in strengthening prevention efforts of Mother-to-Child Transmission of HIV
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 9,097
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Women in the late third trimester of pregnancy/ women near term who were previously HIV un-infected at least 3 months prior to the enrollment visit
- •2. Women who are willing to sign/ provide a thumb impression on the written informed consent form
排除标准
- •1. Women who are not willing for a second HIV test in pregnancy
研究者
相似试验
进行中（未招募）
不适用
Extension study to evaluate long-term-safety of IMA901 plus GM-CSF in advanced renal cell carcinoma patients who achieved a decrease in tumor load or stabilization of their disease after participation in the open-label, multicenter IMA901-202 Phase 2 studyThis extension study will be conducted in men and women with advanced renal cell cancer (RCC) who achieved a decrease in tumor load or stabilization of their disease after participation in the core study IMA901-202.EUCTR2008-000213-30-DEimmatics biotechnologies GmbH20
尚未招募
不适用
A study to compare the efficacy of IV fentanyl versus femoral nerve block for positioning prior to subarachnoid block in patients undergoing fracture femur surgeries.CTRI/2021/03/031677Dr Thanuja N Umesh
已完成
2 期
A phase II study evaluating abscopal effect of nivolumab in combination with local radiotherapy in patients with pretreated metastatic non-small cell lung cancerJPRN-UMIN000023838Department of Respiratory, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine17
招募中
不适用
A follow-up study to evaluate the risk of later development of type 1 diabetes in the gestational diabetes mellitus patients with presence of GAD antibody in Japagestational diabetes mellitusJPRN-UMIN000029438ational Hospital Organization, Kumamoto Medial Center50
进行中（未招募）
1 期
An open-label study to evaluate the extended early bactericidal activity, safety, tolerability and pharmacokinetics of multiple doses (m.d.) of TMC207 oral solution (os) and isoniazid (JH), m.d. of TMC207 os and pyrazinamide (JZ), m.d. of TMC207 os and rifampin (JR) or m. oral d. of TMC207 os and isoniazid and pyrazinamide (JHZ), compared to the 3 principle drugs of standard anti-tuberculosis treatment (HRZ) in treatment-naïve subjects with sputum-smear positive pulmonary tuberculosis. - N/ATuberculosisEUCTR2004-005142-12-GBTibotec Pharmaceuticals Limited60